PMN (40) GNLX (29) PMVP (45) COYA (35) ⌘ Pro Terminal →

Milestone Pharmaceuticals Inc. (MIST) — RQD Stock Rating Cockpit

$0.73 -7.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.72

Milestone Pharmaceuticals Inc. (MIST) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $98.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MIST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MIST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.73 (-7.55% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MIST ranks #350 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MIST compare to PMN and GNLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMN (ProMIS Neurosciences Inc. (ON)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $99.4M) and GNLX (Genelux Corporation) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $95.0M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MIST?

▼

Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $0 in revenue, -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.72 (-1.55%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MIST)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY MIST SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 46 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.81-13.6% Next Q

Q2 (-2Q)

Grade C-$0.70-8.6% Next Q

Q3 (-1Q)

Grade C-$0.64+14.1% Next Q

Current

Grade D$0.73-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MIST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MIST currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.89) and Max Pain ($0.77) forces dealer call-delta covering toward $3.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MIST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MIST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $1$0.73H: $3

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MIST

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like MIST

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MIST)

✓Walkthrough of MIST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MIST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.38%⚡ TESTING RESISTANCE

2026-11-02O $0.77H $0.78L $0.73C $0.73VOL 151.6K

RES: $0.82SUP: $0.60SMA50: $0.89SMA200: $1.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MIST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MIST Butterfly Map → + Track MIST →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MIST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MIST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MIST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MIST)

Health Care Rank #350 of 1016 ⚔️ PMN vs MIST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MIST vs. PMN, GNLX, PMVP, COYA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Pharmaceuticals Inc. (MIST) ranks #350 by composite RQD confidence (47/100, grade D) and #663 by equity capitalization ($98.3M). Within this direct 5-issuer industry benchmark cohort, MIST leads on earnings valuation at N/A trailing P/E, while MIST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MIST currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MIST ACTIVE Milestone Pharmaceuticals Inc.	D	47/100	—	—	-35.0%	-7.55%	$98.3M	Benchmark Subject
PMN ProMIS Neurosciences Inc. (ON)	D-	40/100	—	—	-35.0%	-70.13%	$99.4M	/pmn-vs-mist →
GNLX Genelux Corporation	E	29/100	—	—	-35.0%	-0.95%	$95.0M	/gnlx-vs-mist →
PMVP PMV Pharmaceuticals Inc.	D	45/100	—	—	-35.0%	-2.96%	$101.9M	/pmvp-vs-mist →
COYA Coya Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.30%	$93.4M	/coya-vs-mist →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001408443

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$63.1K, operating cash flow of -$49.0M, and free cash flow of -$49.3M (-70.8% YoY). On the balance sheet, MIST closed FY2025 with $113.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$63.1K	-$49.0M	-$49.3M	$113.6M	—
FY2024 (FY)	2024-12-31	$0	-$41.5K	-$28.8M	-$28.9M	$75.5M	—
FY2023 (FY)	2023-12-31	$0	-$59.7K	-$46.4M	-$46.4M	—	—

3. MIST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MIST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MIST compare to PMN and GNLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MIST?

Where is MIST trading relative to its 50-day, 200-day, and 52-week technical levels?

MIST last traded at $0.73 (-7.55% on volume of 730,167 shares), positioning the stock -17.98% below its 50-day simple moving average ($0.89) and -46.72% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.63 to $3.06, MIST sits at the 4.1% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).

MIST Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MIST stock right now?

Milestone Pharmaceuticals Inc. (MIST) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MIST's 12-month price target and RQD AI Jury consensus?

MIST's 12-month base price target is $0.69 (range $0.54 to $3.21), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MIST RQD Cockpit MIST 12M Forecast MIST Earnings & Move MIST Dividends & DRIP MIST Insiders & 13F MIST Whale Options MIST Profit Sankey MIST News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MIST — Milestone Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:11Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MIST scores 47 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For an investor, this means the business is not generating cash returns on invested capital today, so value depends on future outcomes rather than current earnings power.
Whale 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and is a potential upside-support factor, though the underlying holder data is not provided in this dossier.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low, indicating limited insider-side conviction signals.
Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock's moves are expected to track the broader market rather than diverge from it.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. Solvency-style indicators are middling, while the Piotroski score signals weak fundamental quality.

Taken together, the rating frames MIST as a high-risk, cash-burning name. The key valuation tradeoff is that a market cap of $98.3M against negative operating income leaves little margin for execution error. Upside would depend on catalysts converting into cash flow, while the distribution warning and weak Piotroski reading point to downside risk if sentiment deteriorates.

Business

Milestone Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three periods shown, indicating no revenue recognition in the reported data. Market capitalization is $0.1B per the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-62.1M	$-0.1M	N/A	$-49.3M	$73.0M	N/A
FY 2024	$0.0M	$-42.1M	$-0.0M	N/A	$-28.9M	$25.3M	N/A
FY 2023	$0.0M	$-61.1M	$-0.1M	N/A	$-46.4M	N/A	N/A

Per the SEC financials, operating losses were $-62.1M in FY 2025 and $-42.1M in FY 2024, and free cash flow was negative in every period shown. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity at 0.5. Reported cash rose from $25.3M in FY 2024 to $73.0M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

RISK WATCH (Yahoo Finance, 1h ago): Headline references analysts resetting expectations for Cardamyst and a fair value decline. Light: RED.
MARKET WIRE (TradingView, 3h ago): Estimates-related coverage for NASDAQ:MIST. Light: YELLOW.
CATALYST (Stock Titan, 6h ago): A trial of a nasal spray for fast, irregular heartbeats enrolled its first European patient. Light: GREEN.
CATALYST (Stock Titan, 9h ago): After 30 business days below $1, the company received time to regain compliance with the listing requirement. Light: GREEN.
MARKET WIRE (TradingView, 12h ago): Disclosure of failure to satisfy a continued listing rule or standard. Light: YELLOW.
MARKET WIRE (Kalkine, 15h ago): Coverage listing MIST among Nasdaq compliance watch names. Light: YELLOW.

Per the news feed, the listing-compliance items are the most consequential for a sub-$1 stock. The Cardamyst item carries a RED light and points to downward expectation revisions. The first-European-patient trial enrollment is the only GREEN clinical item in the feed.

Per the butterfly supply-chain graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What products and clinical programs (including Cardamyst) generate the company's catalysts, and what are their stages and timelines?
What are the terms and timeline of the Nasdaq compliance deadline, and what steps are planned if the stock stays below $1?
What drove the cash increase from $25.3M to $73.0M between FY 2024 and FY 2025, and what is the current runway at the FY 2025 FCF rate?
What are the company's debt obligations, since debt is listed as N/A in every period?
What do the 13F and insider data behind the whale and insider pillar scores actually show?

MIST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Milestone Pharmaceuticals Inc. (MIST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MIST Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 3h ago

Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations

Yahoo Finance report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 6h ago

Milestone Pharmaceuticals Inc. Estimates – NASDAQ:MIST

TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 9h ago

A trial of a nasal spray for fast, irregular heartbeats enrolls its first European patient.

Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 12h ago

After 30 business days below $1, Milestone Pharma (Nasdaq: MIST) gets time to regain compliance.

Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 15h ago

Milestone Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 18h ago

Top 5 Nasdaq Compliance Watch Names: Low-Priced Stocks Trading Pre-Market on November 2, 2026

Kalkine report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 21h ago

Milestone Pharmaceuticals (MIST) Slips 1.95% to $0.76 as Shares Sit Between Key Levels - Stop Run

https://www.siam.in/ report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine Media • 1d ago

Milestone Pharmaceuticals Receives Nasdaq Notice for Minimum Bid Price Violation

Kalkine Media report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MIST Bull vs. Bear Conversation Board — What's Your Call at $0.73?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MIST 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.85 (+7.6%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MIST (D • RQD 47/100) a Buy at $0.79?

Welcome to the MIST (Milestone Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.66 (-16.5%)

Spot @ $0.79

Pump the brakes on MIST — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MIST, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Milestone Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.99 (+25.3%)

Spot @ $0.79

MIST cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MIST, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.79 (52-wk range $0.69 - $0.86), any beat on forward guidance forces shorts and underweight funds to chase.